论文部分内容阅读
为了研究乳腺癌HER2表达与预后的关系 ,探讨其作为乳腺癌预后指标的可行性 ,采用免疫组化法 (IHC)检测 185例乳腺癌标本的HER2表达 ,并随访其生存时间。 185例中失访 6 5例 ;12 0例有 10年预后随访资料 ,其中死亡 2 8例。所有检测标本的HER2的阳性率为 37 3%;不同HER2表达级别生存曲线比较差异有统计学意义 ,各生存曲线之间比较差异有统计学意义 ,P值均小于 0 0 1;HER2阴性者 40和 6 0个月生存率比高表达患者高 ;HER2过度表达与生存期呈负相关(P <0 0 5 )。结果说明 ,乳腺癌患者HER2高表达预示生存时间缩短 ,HER2是乳腺癌预后不良的一项独立指标。
In order to study the relationship between the expression of HER2 and the prognosis of breast cancer and explore its feasibility as a prognostic indicator of breast cancer, immunohistochemistry (IHC) was used to detect the expression of HER2 in 185 cases of breast cancer and the survival time was followed up. Of the 185 patients, 65 were lost, and 12 of 10 had 10-year follow-up data, of which 28 were fatal. The positive rate of HER2 in all the specimens was 37.3%. There were significant differences in the survival curves between different HER2 expression levels, with significant differences between the survival curves, P values were less than 0 0 1; HER2-negative 40 And 60-month survival rate were higher than those with high expression. HER2 overexpression was negatively correlated with survival (P <0.05). The results show that high HER2 expression in breast cancer patients predicted shortened survival time, HER2 is an independent indicator of poor prognosis of breast cancer.